Cover Image
市場調查報告書

精巢癌:主要24個市場預測

EPIOMIC EPIDEMIOLOGY SERIES: TESTICULAR CANCER FORECAST IN 24 MAJOR MARKETS 2018-2028

出版商 Black Swan Analysis 商品編碼 599355
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
精巢癌:主要24個市場預測 EPIOMIC EPIDEMIOLOGY SERIES: TESTICULAR CANCER FORECAST IN 24 MAJOR MARKETS 2018-2028
出版日期: 2018年01月01日 內容資訊: 英文 68 Pages
簡介

本報告提供全球主要24個國家的精巢癌的目前患者數 (性別、各年齡世代) 調查分析,目前發病率,加上疾病概要,危險因素,疾病診斷與預後,主要的症狀和併發症等系統性資訊。

調查對象國家

  • 美國
  • 加拿大
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 波蘭
  • 荷蘭
  • 挪威
  • 丹麥
  • 瑞士
  • 俄羅斯
  • 土耳其
  • 沙烏地阿拉伯
  • 南非
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 墨西哥
  • 阿根廷

目錄

  • 圖表
  • 簡介
  • 病因
  • 危險因素和預防
  • 疾病診斷
  • 變異:各地區/民族
  • 疾病預後和臨床過程
  • 疾病相關的主要併發症/特徵
  • 患者數的定量化方法
  • 精巢癌的最大發病率
  • 精巢癌患者的特徵
  • 精巢癌患者的合併症
  • 簡稱
  • 其他服務、解決方案
  • 相關出版
  • 線上流行病學資料庫
  • 線上藥價資料庫
  • 參考文獻
  • 附錄
目錄
Product Code: TEST0020118

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Testicular Cancer in 24 Major Markets

Testicular cancer is a relatively rare cancer; although it is the most commonly diagnosed cancer in males aged 20-34. There are two main types of testicular cancer; seminomas and non-seminomas, which develop from germ cells in the testicles. The standard treatment procedure involves the complete removal of the testis with the tumour.

This report provides the current incident population for testicular cancer across 24 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Denmark, Switzerland, Russia, Turkey, Saudi Arabia, South Africa, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current incidence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of testicular cancer patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of testicular cancer include:

  • Presence of lump in one testis
  • Gynaecomastia
  • Pain (lower back, scrotum or lower abdomen)
  • Cryptorchidism
  • Hypospadias

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global testicular cancer market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the incidence of the subdivided types of testicular cancer and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific co-morbid conditions on the incident population of testicular cancer patients.
  • Identification of testicular cancer patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of thyroid cancer patients.

TABLE OF CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • ADDITIONAL DATA AVAILABLE ON REQUEST
  • TOP-LINE INCIDENCE FOR TESTICULAR CANCER
  • FEATURES OF TESTICULAR CANCER PATIENTS
  • TUMOUR TYPE
  • TUMOUR LOCATION
  • TUMOUR DISSEMINATION AND STAGING
  • CLINICAL PARAMETERS OF TESTICULAR CANCER PATIENTS
  • COMORBIDITIES OF TESTICULAR CANCER PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. AJCC tumour classification in testicular cancer patients
  • Table 2. Incidence of testicular cancer, males (000s)
  • Table 3. Patients with testicular cancer by type/histopathology of the tumour, males (000s)
  • Table 4. Patients with germ-cell testicular cancer by subtype of the tumour, males (000s)
  • Table 5. Patients with testicular cancer by location of the tumour, males (000s)
  • Table 6. Patients with testicular cancer by laterality of the tumour, males (000s)
  • Table 7. Patients with testicular cancer by lymph node and metastasis status, males (000s)
  • Table 8. Patients with testicular cancer by AJCC stage of the tumour, males (000s)
  • Table 9. Patients with testicular cancer by serum alpha fetoprotein levels [ng/mL], males (000s)
  • Table 10. Patients with testicular cancer by serum hCG levels [mIU/mL], males (000s)
  • Table 11. Patients with testicular cancer by serum LDH levels, males (000s)
  • Table 12. Testicular cancer patients with cachexia, males (000s)
  • Table 13. Abbreviations and acronyms used in the report
  • Table 14. USA incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 15. Canada incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 16. France incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 17. Germany incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 18. Italy incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 19. Spain incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 20. UK incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 21. Poland incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 22. Netherlands incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 23. Norway incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 24. Denmark incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 25. Switzerland incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 26. Russia incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 27. Turkey incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 28. Saudi Arabia incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 29. South Africa incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 30. Japan incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 31. China incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 32. South Korea incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 33. India incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 34. Australia incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 35. Brazil incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 36. Mexico incidence of testicular cancer by 5-yr age cohort, males (000s)
  • Table 37. Argentina incidence of testicular cancer by 5-yr age cohort, males (000s)
Back to Top